Occudo Quantitative Strategies LP Has $74,000 Stake in Sensus Healthcare, Inc. (NASDAQ:SRTS)

Occudo Quantitative Strategies LP trimmed its stake in Sensus Healthcare, Inc. (NASDAQ:SRTS) by 32.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,692 shares of the company’s stock after selling 5,057 shares during the period. Occudo Quantitative Strategies LP owned about 0.07% of Sensus Healthcare worth $74,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of SRTS. Ritholtz Wealth Management grew its position in Sensus Healthcare by 65.3% in the 4th quarter. Ritholtz Wealth Management now owns 51,261 shares of the company’s stock worth $355,000 after purchasing an additional 20,256 shares during the last quarter. Sigma Planning Corp acquired a new stake in shares of Sensus Healthcare during the 4th quarter valued at about $215,000. IFP Advisors Inc acquired a new stake in shares of Sensus Healthcare during the 4th quarter valued at about $95,000. Virtu Financial LLC acquired a new stake in shares of Sensus Healthcare during the 4th quarter valued at about $189,000. Finally, JPMorgan Chase & Co. acquired a new stake in shares of Sensus Healthcare during the 4th quarter valued at about $27,000. 25.30% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Lake Street Capital decreased their target price on shares of Sensus Healthcare from $18.00 to $13.00 and set a “buy” rating on the stock in a research report on Tuesday, March 11th. HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of Sensus Healthcare in a research report on Friday, April 4th.

Sensus Healthcare Stock Down 4.3%

Shares of SRTS stock opened at $4.46 on Monday. Sensus Healthcare, Inc. has a 12-month low of $4.01 and a 12-month high of $9.33. The company has a market capitalization of $73.57 million, a P/E ratio of 11.15 and a beta of 1.30. The firm has a 50-day moving average price of $4.61 and a 200 day moving average price of $6.12.

Sensus Healthcare (NASDAQ:SRTS) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.20). Sensus Healthcare had a net margin of 15.90% and a return on equity of 12.60%. The firm had revenue of $8.34 million for the quarter, compared to the consensus estimate of $7.23 million. As a group, research analysts expect that Sensus Healthcare, Inc. will post 0.32 earnings per share for the current year.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.